Silo Pharma, Inc.(SILO)Earnings, Financials & Key Ratios

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA. , June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that it has engaged its drug-device development partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system used for nose-to-brain delivery of SPC-15, the Company's lead intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA. , June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.